Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
 Disease Category: Rheumatoid Arthritis
Location: United States, NJ

Trial Information

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

Patient Inclusion Criteria:

  • Able and willing to give written informed consent and comply with requirements of the study protocol.
  • RA patients who never used biologic medications.
  • RA patients who are on Methotrexate or used it in the past.

Patient Exclusion Criteria:

  • Current or previous evidence of serious uncontrolled cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease.

Fay Chen RN, Clinical Research Coordinator
UMDNJ-Robert Wood Johnson Medical School
Clinical Research Center Acute Care Building, 3rd floor 51 French Street
New Brunswick, NJ 08903
Phone: 732-418-8484
Fax: 732-418-8480
Email: chenf2@umdnj.edu

View Map

Research Center Information: UMDNJ-Robert Wood Johnson Medical School

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.